tofacitinib cream (CGB 500) / CAGE Bio - LARVOL DELTA

CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial (PRNewswire) - "The trial met primary and secondary endpoints, demonstrating best-in-class treatment success, rapid itch reduction, and a favorable safety profile. 59% of patients achieved Investigator's Global Assessment (IGA) treatment success....35% achieved complete itch resolution ('0' itch score)."

P2b data • Atopic Dermatitis

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (clinicaltrials.gov) - P2 | N=3 | Not yet recruiting | Sponsor: CAGE Bio Inc.

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: CAGE Bio Inc. | Not yet recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: CAGE Bio Inc.

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology